Evidence map›Paper›PMID 42410069›Full record

ArticleNature structural & molecular biology2026

Promoter reinforcement supports transcriptional resilience in drug-resistant cancer.

Vasumathi Kameswaran, Sayantanee Paul, Daniel Le, Alissa D Guarnaccia, Jonathan Hoover, Liang-Fu Chen, Thijs J Hagenbeek, Minyi Shi, Luke Y Zhao, Jessica M Lund and 8 more

Abstract read
In one paragraph

Article in Nature structural & molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Vasumathi KameswaranDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2552-6183
Sayantanee PaulDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Daniel LeDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Alissa D GuarnacciaDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4195-2158
Jonathan HooverDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Liang-Fu ChenDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Thijs J HagenbeekDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Minyi ShiDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Luke Y ZhaoDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Jessica M LundDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Ana Xavier-MagalhãesDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Julia LauDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0009-0007-4130-988X
Marco De SimoneDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Yuxin LiangDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Antonina HafnerDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Anwesha DeyDepartment of Discovery Oncology, Genentech Inc., South San Francisco, CA, USA.
Zora ModrusanDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA.
Bence DanielDepartment of Proteomic and Genomic Technologies, Genentech Inc., South San Francisco, CA, USA. daniel.bence@gene.com.ORCID http://orcid.org/0000-0002-2410-8767

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In mammalian cells, gene-distal regulatory elements enable long-range gene regulation and support cell-type-specific transcriptional programs. This regulatory architecture is frequently perturbed in cancer, particularly when oncogenic transcription factors are targeted therapeutically. However, how cancer cells adapt under such selective pressure has remained poorly understood. Here we show that mesothelioma cells dependent on the oncogenic TEAD family of transcription factors acquire resistance to a pan-TEAD inhibitor. Such resistance is accompanied by a promoter-centric regulatory mechanism, a process we term promoter reinforcement, to sustain gene expression following TEAD inhibition. Using base-pair-resolution Micro Capture-C on a set of TEAD target genes, we find that regulatory element-promoter interactions are weakened or lost in resistant cells, even as promoter activity and gene expression recover in the context of partial epigenetic restoration. Mechanistically, resistance-induced transcription factors show promoter-biased localization and can increase promoter activity, whereas distal regulatory element function can become dispensable. Together, these findings identify promoter reinforcement as a locus-specific compensatory response that supports transcriptional resilience under TEAD inhibition, indicating promoter-associated vulnerabilities in drug-resistant cancer.

Indexed as

DNA-Binding ProteinsDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticPromoter Regions, GeneticTranscription FactorsTranscription, GeneticAnimalsCell Line, TumorHumansTEA Domain Transcription FactorsDNA-Binding ProteinsTEA Domain Transcription FactorsTranscription Factors

Identifiers

PMID42410069
PMCPMC13372675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.